share_log

卫宁健康获中国银河买入评级,WiNEX产品拓展较好,人效提升显著

JRJ Finance ·  Apr 22 11:01

4月22日,卫宁健康获中国银河买入评级,近一个月卫宁健康获得2份研报关注。

研报预计,公司2024-2026年实现营收37.36/43.49/49.07亿,同比增长18.1%/16.4%/12.8%;实现归母净利润5.63/7.16/8.57亿,同比增长57.4%/27.2%/19.6%。研报认为,2023年公司在全国拓展了数百家WiNEX客户,WiNEX产品以数字化转型赋能医院高质量发展。公司2023年在智慧医院及医院平台、医共体/医联体、基层卫生等领域新增60余个千万级项目。

风险提示:并购重组风险;创新业务持续亏损风险。

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment